Press Releases

Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference

August 8, 2018 at 4:05 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 8, 2018-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company is scheduled to present at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14th, at 9:10 a.m. ET.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors and Media section of the company’s website at A replay of the webcast will be archived on the Magenta website for 30 days following the presentation.

About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients by making the process more effective, safer and easier.

Forward-Looking Statement
This press release may contain forward-looking statements, including statements regarding Magenta’s financing plans, clinical trials and product candidate development. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current beliefs, expectations and assumptions regarding the future of Magenta’s business, future plans and strategies, development plans, clinical results and other future conditions. Such statements are subject to certain risks and uncertainties, including, but not limited to: uncertainties related to the initiation and conduct of trials and studies and other development requirements for Magenta’s product candidates; the risk that any one or more of Magenta’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical trials will not be predictive of future results in connection with future studies or trials; risks related to Magenta’s ability to protect and maintain its intellectual property position; and risks related to Magenta’s relationships with third parties. Although Magenta's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Magenta's programs and operations are described in additional detail in its registration statement on Form S-1 and in the company's other filings from time to time with the SEC. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Source: Magenta Therapeutics

Magenta Therapeutics:
Manisha Pai, 857-242-1155
Vice President, Communications & Investor Relations